Share chart Amarin
Extended chart
Simple chart
About Amarin
Amarin Corporation — биофармацевтическая компания, основанная в 1993 году. Основана в 1993, располагается в Бедминстере, Нью-Джерс, США. Разрабатывает лекарства для лечения кардиоваскулярных заболеваний. Лекарство: https://www.vascepa.com/ https://finance.yahoo.com/quote/AMRN/profile?p=AMRN https://www.bloomberg.com/quote/AMRN:US| IPO date | 1993-04-01 |
|---|---|
| ISIN | US0231112063 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | http://www.amarincorp.com |
| Цена ао | 0.459 |
| Change price per day: | -0% (0.459) |
|---|---|
| Change price per week: | -0.2174% (0.46) |
| Change price per month: | -20.17% (0.575) |
| Change price per 3 month: | +0.5036% (0.4567) |
| Change price per half year: | -21.31% (0.5833) |
| Change price per year: | -48.38% (0.8892) |
| Change price per 3 year: | -85.7% (3.21) |
| Change price per 5 year: | -90.48% (4.82) |
| Change price per 10 year: | -75.59% (1.88) |
| Change price per year to date: | -5.36% (0.485) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| Sarissa Capital Management, LP | 24850623 | 25.15 |
| Kynam Capital Management, LP | 12022957 | 12.17 |
| Eversept Partners, LP | 6095505 | 6.17 |
| Morgan Stanley | 5563083 | 5.63 |
| DG Capital Management, LLC | 5405438 | 5.47 |
| Two Sigma Investments, LP | 3184293 | 3.22 |
| Tang Capital Management, LLC | 3086544 | 3.12 |
| Two Sigma Advisers, LP | 2727602 | 2.76 |
| Millennium Management LLC | 2538596 | 2.57 |
| SCP Investment, LP | 2500000 | 2.53 |
| ETF | Share, % | Profitability for 1 year, % | Dividends, % |
|---|---|---|---|
| ProShares UltraShort Nasdaq Biotechnology | 0.85 | -40.36 | 1.76 |
| Principal Healthcare Innovators ETF | 0.02403 | 618.5 | 0.8416 |
| Future Tech ETF | 0.02403 | 426.34 | 0.8416 |
| Invesco Nasdaq Biotechnology ETF | 0.02306 | 28.58 | 0.8565 |
| ProShares Ultra Nasdaq Biotechnology | 0.01596 | 51.7 | 0.85651 |
| SPDR S&P International Small Cap ETF | 0.01199 | 8.94 | 3.10348 |
SPDR Portfolio Developed World ex-US ETF
|
0.00069 | 5.29 | 3.28401 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Mr. Aaron D. Berg | CEO & President | 1.26M | 1963 (62 years) |
| Dr. Steven B. Ketchum Ph.D. | Executive VP, President of Research & Development and Chief Scientific Officer | 1.16M | 1965 (60 years) |
| Mr. Jordan Zwick | Senior VP of Corporate Business Development & Investor Relations | N/A | 1987 (38 years) |
| Dr. David Keenan Ph.D. | Executive VP of Technical Operations & President of Europe | N/A | |
| Mr. Laurent Abuaf | President of Europe & Senior VP | N/A | |
| Dr. Nabil Abadir | Chief Medical Officer of Global Medical Affairs | N/A | |
| Mr. Jonathan N. Provoost | Executive VP, Chief Legal & Compliance Officer and Secretary | 160.08k | 1970 (55 years) |
| Mr. Thomas Charles Reilly | Executive VP, CFO & Global Head of HR | 1972 (53 years) |
Address: Ireland, Dublin , Grand Canal Docklands - open in Google maps, open in Yandex maps
Website: http://www.amarincorp.com
Website: http://www.amarincorp.com
